In Depth 22 Nov 2023 Apellis’ Syfovre vs Astellas’ Izervay: the battle for a geographic atrophy treatment Until the approval of Apellis’ Syfovre earlier this year, there was no treatment for geographic atrophy. Shortly after, Astellas’ Izervay was also approved for the eye condition. Now, as the only two companies with approved geographic atrophy treatments, there appears to be an ongoing rivalry between them to see who can come out on top […] November 22, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Nov 2023 Beyond insulin: six cutting-edge diabetes biotech companies you should know about As we predicted last year, the diabetes market is booming, particularly after the incredible success of new diabetes drugs like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro. There are now several diabetes biotech companies that are garnering attention, all with their own innovative solutions to tackling both type 1 and type 2 diabetes. The prevalence […] November 21, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 16 Nov 2023 Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again Between 2020 and 2022 – largely due to the biotech innovations that came about by the COVID-19 pandemic – there was an influx of generalist investors in the biotech industry, betting big on new technologies like mRNA vaccines. But, now, these investors appear to have backed off, leaving room for specialized biotech venture capital (VC) […] November 16, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 14 Nov 2023 10 biotech companies leading innovation in the Asia-Pacific region Asia-Pacific is now establishing itself as a global innovation hub, with China, Japan, and Korea leading the space in overall innovative pipeline assets in the region. The life sciences industry is thriving, and there has been a shift in the region from predominantly producing generics to developing innovative technologies, with several Asia-Pacific biotech companies leading […] November 14, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Weekly Roundup 10 Nov 2023 Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under the name Korro Bio, Inc. […] November 10, 2023 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 6 Nov 2023 The biggest private biotech investments in October 2023 The companies Aiolos Bio, MapLight Therapeutics and Agomab Therapeutics bagged the biggest biotech investments in October 2023. Around the world, biomaterials, central nervous system and musculoskeletal disorder players attracted the most investor interest. October 2023 saw a lot of fundraising taking place both in and out of healthcare in the U.S. and Europe. However, the […] November 6, 2023 - 3 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 2 Nov 2023 How French pharma giant Sanofi is betting big on AI The benefits of artificial intelligence (AI) in shaping clinical research and trials have given rise to many new AI-driven biotech startups. According to a recent report, the number of AI companies involved in drug discovery and development increased from 62 in 2011 to 400 in 2022. This AI-driven transformation is catching the attention of big pharma […] November 2, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 30 Oct 2023 The ongoing search for an HIV cure: can CRISPR crack the code? HIV continues to represent a global health burden, with the World Health Organization (WHO) estimating that, in 2022, there were 39 million people living with the virus. But there is still no effective cure for it. The only option patients have is antiretroviral therapy, which, although it represents a major milestone in HIV treatment and […] October 30, 2023 - 7 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 26 Oct 2023 Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials Alzheimer’s disease is the most common form of dementia – which currently affects more than 55 million people globally – making up 60% to 70% of cases. It is a complex disease, encompassing multiple interrelated and progressive destructive processes in the brain, resulting in neuron damage that extends to parts of the brain that enable […] October 26, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 24 Oct 2023 Seven molecular glue startups looking to stick around in the biotech industry Since they were discovered around three decades ago, molecular glues have come a very long way as a therapeutic option for several different disease areas, including cancer and neurodegenerative disorders. Now, there are a rising number of molecular glue companies hoping to show clinical success with their candidates. The term molecular glue refers to a […] October 24, 2023 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 20 Oct 2023 Is Africa ready to become the next big biopharma and vaccine manufacturing destination? Localizing pharma manufacturing worldwide is an extremely important step, and it holds particular significance for Africa. The continent is more vulnerable to disease burdens and lags behind other continents when it comes to vaccine and general healthcare access. Localized manufacturing could help people in Africa gain easier and more affordable access to vaccines and other […] October 20, 2023 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 19 Oct 2023 Biotech’s battle against NASH: The ongoing pursuit of an effective treatment NASH is one of the most common reasons for a patients receiving a liver transplant. The condition is a severe form of non-alcoholic fatty liver disease (NAFLD), whereby fat builds up on the liver, potentially leading to liver damage or cirrhosis. And, yet, despite the severity of the disease, there are still no approved NASH […] October 19, 2023 - 8 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email